15 completed. 15 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 15 |
| Phase 3 | 2 | Completed 2 |
Follow ziprasidone: new trials by email Literature Review of ziprasidone trials Research Report on ziprasidone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication ASP4345, placebo, risperidone - Schizophrenia | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 233 | 2018-07-13 | 2024-11-12 |
| Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs Ziprasidone, Placebo - Major Depressive Disorder | Phase 2 | Completed | Massachusetts General Hospital | 458 | 2008-07-01 | 2014-07-03 |
| A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder Ziprasidone, Placebo - Major Depressive Disorder | Phase 2 | Completed | Massachusetts General Hospital | 120 | 2008-03-01 | 2014-07-03 |
| Ziprasidone in the Psychosis Prodrome ziprasidone, placebo - Psychosis Prodrome | Phase 2 | Completed | Yale University | 51 | 2008-03-01 | 2023-03-27 |
| Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia Galantamine, CDP-choline, Placebo - Schizophrenia | Phase 2 | Completed | Georgetown University | 43 | 2007-11-01 | 2018-04-11 |
| Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State ziprasidone (Geodon), placebo - Bipolar Disorder, Bipolar Depression | Phase 2 | Completed | Tufts Medical Center | 73 | 2006-12-01 | 2016-07-29 |
| Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders Ziprasidone Hydrochloride, Placebo - Conduct Disorder, Oppositional Defiant Disorder | Phase 2 | Completed | University Hospital Freiburg | 51 | 2006-07-01 | 2008-11-18 |
| The MIND Study: Modifying the INcidence of Delirium Ziprasidone, Haloperidol, Placebo - Delirium, Cognition Disorders | Phase 2 | Completed | Vanderbilt University | 102 | 2004-12-01 | 2016-01-29 |
| Geodon for the Treatment of Refractory Social Anxiety Disorder Ziprasidone, Sertraline - Social Anxiety Disorder | Phase 2 | Completed | Duke University | 51 | 2004-11-01 | 2014-10-31 |
| Ziprasidone in the Treatment of Borderline Personality Disorder ziprasidone, Placebo - Borderline Personality Disorder | Phase 2 | Completed | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 60 | 2004-03-01 | 2008-03-14 |
| A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders Ziprasidone - Schizophrenia, Bipolar Disorder | Phase 2 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 63 | 2003-12-01 | 2021-02-21 |
| Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder Ziprasidone - Schizophrenia, Schizoaffective Disorder | Phase 2 / Phase 3 | Completed | Manhattan Psychiatric Center | 57 | 2003-09-01 | 2011-07-29 |
| Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression Ziprasidone, Sertraline, Haloperidol - Affective Disorders | Phase 2 / Phase 3 | Completed | Duke University | 72 | 2003-04-01 | 2014-08-19 |
| Ziprasidone in Early Onset Schizophrenia Spectrum Disorders Ziprasidone - Schizophrenia | Phase 2 | Completed | University of North Carolina, Chapel Hill | 40 | 2002-12-01 | 2024-08-15 |
| Ziprasidone in Children With Autism: A Pilot Study Ziprasidone - Autism | Phase 2 | Completed | Drexel University College of Medicine | 15 | 2002-02-01 | 2010-06-17 |
Schizophrenia (6) · Psychotic Disorders (4) · Depression (3) · Depressive Disorder, Major (3) · Bipolar Disorder (2) · Anxiety Disorders (1) · Autistic Disorder (1) · Borderline Personality Disorder (1) · Child Development Disorders, Pervasive (1) · Cognition Disorders (1) · Conduct Disorder (1) · Critical Illness (1) · Delirium (1) · Depressive Disorder, Treatment-Resistant (1) · Diabetes Mellitus (1)
Duke University (2) · Massachusetts General Hospital (2) · Astellas Pharma Global Development, Inc. (1) · Drexel University College of Medicine (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Georgetown University (1) · Manhattan Psychiatric Center (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · Tufts Medical Center (1) · University Hospital Freiburg (1) · University of North Carolina, Chapel Hill (1) · Vanderbilt University (1) · Yale University (1)
United States (13) · Canada (1) · Egypt (1) · Germany (1) · India (1) · Spain (1)
George I Papakostas, M.D. (2) · Adel Elsheshai, MD (1) · Andrew Winokur, M.D. (1) · Christian Fleischhaker, MD (1) · E Wesley Ely, MD, MPH (1) · Eberhard Schulz, MD (1) · Frederick Cassidy, MD (1) · George Simpson, MD (1) · Gustavo Kinrys, M.D. (1) · Jean-Pierre Lindenmayer, M.D. (1) · John M Zajecka, M.D. (1) · Klaus Hennighausen, MD (1) · Linmarie Sikich, MD (1) · Mahmoud S Okasha, MD (1)
PMID 18251623, PMID 19818257, PMID 20095068, PMID 22545088, PMID 23290327, PMID 25659187, PMID 26085041, PMID 27306192, PMID 27835715, PMID 32533536, PMID 36375174
R34MH077849 (1)